Behnam Sabayan1, Jeroen van der Grond, Rudi G Westendorp, J Wouter Jukema, Ian Ford, Brendan M Buckley, Naveed Sattar, Matthias J P van Osch, Mark A van Buchem, Anton J M de Craen. 1. From the Departments of Radiology (B.S., J.v.d.G., M.J.P.v.O., M.A.v.B.), Gerontology and Geriatrics (B.S., R.G.W., A.J.M.d.C.), and Cardiology (J.W.J.), Leiden University Medical Center; Netherlands Consortium for Healthy Ageing (R.G.W., A.J.M.d.C.), Leiden, the Netherlands; Robertson Center for Biostatistics (I.F.), and Glasgow Cardiovascular Research Centre (N.S.), University of Glasgow, UK; and Department of Pharmacology and Therapeutics (B.M.B.), University College Cork, Ireland.
Abstract
OBJECTIVE: To examine the association of total cerebral blood flow (CBF) with all-cause, noncardiovascular, and cardiovascular mortality in older subjects at risk of cardiovascular disease. METHODS: We included 411 subjects with a mean age of 74.5 years from the MRI substudy of the Prospective Study of Pravastatin in the Elderly at Risk. Total CBF was measured at baseline, and occurrence of death was recorded in an average follow-up period of 11.8 years. For each participant, total CBF was standardized for brain parenchymal volume. Cox regression models were used to estimate risk of all-cause, noncardiovascular, and cardiovascular mortality in relation to CBF. RESULTS: Mortality rates among participants in low, middle, and high thirds of total CBF were 52.1, 41.5, and 28.7 per 1,000 person-years, respectively. Compared with participants in the high third of CBF, participants in the low third had 1.88-fold (95% confidence interval [CI]: 1.30-2.72) higher risk of all-cause mortality, 1.66-fold (95% CI: 1.06-2.59) higher risk of noncardiovascular mortality, and 2.50-fold (95% CI: 1.28-4.91) higher risk of cardiovascular mortality. Likewise, compared with participants in the high third of CBF, participants in the middle third had 1.44-fold (95% CI: 0.98-2.11) higher risk of all-cause mortality, 1.29-fold (95% CI: 0.82-2.04) higher risk of noncardiovascular mortality, and 1.86-fold (95% CI: 0.93-3.74) higher risk of cardiovascular mortality. These associations were independent of prevalent vascular status and risk factors. CONCLUSIONS: Low total CBF is linked with higher risk of all-cause, noncardiovascular, and cardiovascular mortality in older people independent of clinical cardiovascular status.
OBJECTIVE: To examine the association of total cerebral blood flow (CBF) with all-cause, noncardiovascular, and cardiovascular mortality in older subjects at risk of cardiovascular disease. METHODS: We included 411 subjects with a mean age of 74.5 years from the MRI substudy of the Prospective Study of Pravastatin in the Elderly at Risk. Total CBF was measured at baseline, and occurrence of death was recorded in an average follow-up period of 11.8 years. For each participant, total CBF was standardized for brain parenchymal volume. Cox regression models were used to estimate risk of all-cause, noncardiovascular, and cardiovascular mortality in relation to CBF. RESULTS: Mortality rates among participants in low, middle, and high thirds of total CBF were 52.1, 41.5, and 28.7 per 1,000 person-years, respectively. Compared with participants in the high third of CBF, participants in the low third had 1.88-fold (95% confidence interval [CI]: 1.30-2.72) higher risk of all-cause mortality, 1.66-fold (95% CI: 1.06-2.59) higher risk of noncardiovascular mortality, and 2.50-fold (95% CI: 1.28-4.91) higher risk of cardiovascular mortality. Likewise, compared with participants in the high third of CBF, participants in the middle third had 1.44-fold (95% CI: 0.98-2.11) higher risk of all-cause mortality, 1.29-fold (95% CI: 0.82-2.04) higher risk of noncardiovascular mortality, and 1.86-fold (95% CI: 0.93-3.74) higher risk of cardiovascular mortality. These associations were independent of prevalent vascular status and risk factors. CONCLUSIONS: Low total CBF is linked with higher risk of all-cause, noncardiovascular, and cardiovascular mortality in older people independent of clinical cardiovascular status.
Authors: Stephen M Smith; Mark Jenkinson; Mark W Woolrich; Christian F Beckmann; Timothy E J Behrens; Heidi Johansen-Berg; Peter R Bannister; Marilena De Luca; Ivana Drobnjak; David E Flitney; Rami K Niazy; James Saunders; John Vickers; Yongyue Zhang; Nicola De Stefano; J Michael Brady; Paul M Matthews Journal: Neuroimage Date: 2004 Impact factor: 6.556
Authors: J Shepherd; G J Blauw; M B Murphy; S M Cobbe; E L Bollen; B M Buckley; I Ford; J W Jukema; M Hyland; A Gaw; A M Lagaay; I J Perry; P W Macfarlane; A E Meinders; B J Sweeney; C J Packard; R G Westendorp; C Twomey; D J Stott Journal: Am J Cardiol Date: 1999-11-15 Impact factor: 2.778
Authors: Jie J Cao; Alice M Arnold; Teri A Manolio; Joseph F Polak; Bruce M Psaty; Calvin H Hirsch; Lewis H Kuller; Mary Cushman Journal: Circulation Date: 2007-06-18 Impact factor: 29.690
Authors: Sanaz Sedaghat; Meike W Vernooij; Elizabeth Loehrer; Francesco U S Mattace-Raso; Albert Hofman; Aad van der Lugt; Oscar H Franco; Abbas Dehghan; M Arfan Ikram Journal: J Am Soc Nephrol Date: 2015-08-06 Impact factor: 10.121
Authors: Otto Mølby Henriksen; Naja Liv Hansen; Merete Osler; Erik Lykke Mortensen; Dorte Merete Hallam; Esben Thade Pedersen; Michael Chappell; Martin Johannes Lauritzen; Egill Rostrup Journal: PLoS One Date: 2017-01-17 Impact factor: 3.240
Authors: Abd R A Ismaili; Mark B Vestergaard; Adam E Hansen; Henrik B W Larsson; Helle H Johannesen; Ian Law; Otto M Henriksen Journal: PLoS One Date: 2018-06-07 Impact factor: 3.240
Authors: Mark Bitsch Vestergaard; Ulrich Lindberg; Niels Jacob Aachmann-Andersen; Kristian Lisbjerg; Søren Just Christensen; Peter Rasmussen; Niels Vidiendal Olsen; Ian Law; Henrik Bo Wiberg Larsson; Otto Mølby Henriksen Journal: J Magn Reson Imaging Date: 2016-09-13 Impact factor: 4.813